The Effects of N-Acetylcysteine as Adjuvant Therapy To Reduce TNF-Α Level And Increase SPO2/FIO2 Ratio In Improving Hypoxemia In COVID-19 Patients
Downloads
Tumor Necrosis Factor Alpha (TNF-α) is a pro-inflammatory cytokine that plays a crucial role in COVID-19 disease progression. N-acetylcysteine (NAC) works throughout several GSH-mediated mechanisms and is known to eliminate oxidative stress in acute respiratory distress syndrome (ARDS) in COVID-19. This study aims to analyze the effect of the N-Acetylcysteine as Adjuvant Therapy to reduce TNF-α levels and Increase SpO2/FiO2 ratio in Improving hypoxemia in COVID-19 Patients. This is a quasi-experimental, non-equivalent control group design study. There were 91 subjects selected using non-random sampling, which consisted of 75 patients in the NAC group and 16 patients in the control group. The TNF-α level was measured using the ELISA method, and SpO2/FiO2 ratio was calculated on day 1 (on admission) and day eight after NAC 5000mg/ 72 hours was given. Statistical analysis was conducted using Wilcoxon and Mann-Whitney U Test. There is a significant decrease in TNF-α level in the treatment group (median 1.49±5.22) (p=0.016) compared with the control group (median 1.64±1.99) (p=0.005). The Median SpO2/FiO2 ratio on day 1 is 163.70±69.64 in the control group and 121.49±40.41 in the treatment group (p=0.005). The Median SpO2/FiO2 ratio on day 8 is 249.69±132.26 in the control group and 151.29±59.18 in the treatment group (p=0.001). There is a positive correlation between serum TNF-α level and SpO2/FiO2 ratio after administration of adjuvant therapy NAC (r=0.240, p=0.038). There is a positive correlation and significant decrease of serum TNF-α and SpO2/FiO2 ratio after adjuvant NAC therapy, which improves hypoxemia in COVID-19 patients.
Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine storm in COVID-19: the current evidence and treatment strategies. Frontiers in immunology. 2020 Jul 10;11:1708.
World Health Organization. Rational use of personal protective equipment (PPE) for coronavirus disease (COVID-19): interim guidance, 19 March 2020. World Health Organization; 2020.
Cron RQ, Behrens EM, editors. Cytokine storm syndrome. Springer Nature; 2019 Sep 9.
Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. InSeminars in immunopathology 2017 Jul (Vol. 39, No. 5, pp. 529-539). Springer Berlin Heidelberg.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020 Feb 15;395(10223):497-506.
Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we know so far. Frontiers in immunology. 2020 Jun 16;11:1446.
Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine & growth factor reviews. 2020 Jun 1;53:25-32.
Tufan A, Güler AA, Matucci-Cerinic M. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turkish journal of medical sciences. 2020 Apr 21;50(SI-1):620-32.
De Flora S, Balansky R, La Maestra S. Rationale for the use of N"acetylcysteine in both prevention and adjuvant therapy of COVID"19. The FASEB journal. 2020 Oct;34(10):13185-93.
Griendling KK, Sorescu D, Ushio-Fukai M. NAD (P) H oxidase: role in cardiovascular biology and disease. Circulation research. 2000 Mar 17;86(5):494-501.
Poe FL, Corn J. N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2. Medical hypotheses. 2020 Oct 1;143:109862.
Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, Ferrucci L, Gilroy DW, Fasano A, Miller GW, Miller AH. Chronic inflammation in the etiology of disease across the life span. Nature medicine. 2019 Dec;25(12):1822-32.
Gallo Marin B, Aghagoli G, Lavine K, Yang L, Siff EJ, Chiang SS, Salazar"Mather TP, Dumenco L, Savaria MC, Aung SN, Flanigan T. Predictors of COVID"19 severity: A literature review. Reviews in medical virology. 2021 Jan;31(1):1-0.
Shah VK, Firmal P, Alam A, Ganguly D, Chattopadhyay S. Overview of immune response during SARS-CoV-2 infection: lessons from the past. Frontiers in immunology. 2020 Aug 7;11:1949.
Niles MA, Gogesch P, Kronhart S, Ortega Iannazzo S, Kochs G, Waibler Z, Anzaghe M. Macrophages and Dendritic Cells Are Not the Major Source of Pro-Inflammatory Cytokines Upon SARS-CoV-2 Infection. Frontiers in Immunology. 2021 May 26;12:1984.
Wong KK, Lee SW, Kua KP. N-Acetylcysteine as Adjuvant Therapy for COVID-19–A Perspective on the Current State of the Evidence. Journal of inflammation research. 2021;14:2993.
Avdeev SN, Gaynitdinova VV, Merzhoeva ZM, Berikkhanov ZG. N-acetylcysteine for the treatment of COVID-19 among hospitalized patients. The Journal of Infection. 2021 Jul 10.
Ibrahim H, Perl A, Smith D, Lewis T, Kon Z, Goldenberg R, Yarta K, Staniloae C, Williams M. Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine. Clinical Immunology. 2020 Oct 1;219:108544.
Alamdari DH, Moghaddam AB, Amini S, Keramati MR, Zarmehri AM, Alamdari AH, Damsaz M, Banpour H, Yarahmadi A, Koliakos G. Application of methylene blue-vitamin C–N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial. European journal of pharmacology. 2020 Oct 15;885:173494.
de Alencar JC, Moreira CD, Müller AD, Chaves CE, Fukuhara MA, da Silva EA, Miyamoto MD, Pinto VB, Bueno CG, Lazar Neto F, Gomez Gomez LM. Double-blind, randomized, placebo-controlled trial with N-acetylcysteine for treatment of severe acute respiratory syndrome caused by Coronavirus Disease 2019 (COVID-19). Clinical Infectious Diseases. 2021 Jun 1;72(11):e736-41.
Zhang Q, Ju Y, Ma Y, Wang T. N-acetylcysteine improves oxidative stress, and inflammatory response in patients with community-acquired pneumonia: A randomized controlled trial. Medicine (Baltimore). 2018;97(45). e13087.
Špela Šalamon , Barbara Kramar , Tinkara Pirc Marolt , Borut Poljšak, Irina Milisav. Medical and Dietary Uses of N-Acetylcysteine. Antioxidants. 2019; 8: 1-16.
Shi, T., Yang, X., Zhou, H., XI, J., Sun, J., Ke, Y., et al. Activated carbon N-acetylcysteine microcapsule protects against nonalcoholic fatty liver disease in young rats via activating telomerase and inhibiting apoptosis. PLoS One 2018, 13, e0189856.
Luciano B. Silva, at al. Therapeutic approaches for tumor necrosis factor inhibition. Brazilian Journal of Pharmaceutical Sciences. 2019; 47 (3): 427- 446Md Jahidul Hasan. N-acetylcysteine in Severe COVID-19: The Possible Mechanism. Int J Infect. 2020 October; 7(4):e106361.
Li G Fan Y et al. Coronavirus infections and immune responses. Journal of Medical Virology 2020; 92 (4): 424-432.
Dinicola, S., De Grazia, S., Carlomagno, G., Pintucci, J.P. N-acetylcysteine as a potent molecule to destroy bacterial biofilms. A systematic review. Eur. Rev. Med. Pharmacol. Sci. 2014, 18, 2942–2948.Di Wu, Tiantian Wu, Qun Liu, Zhicong Yang. The SARS-CoV-2 outbreak: What we know. International Journal of Infectious Diseases 94 (2020) 44–48
Copyright (c) 2021 Indonesian Journal of Tropical and Infectious Disease
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The Indonesian Journal of Tropical and Infectious Disease (IJTID) is a scientific peer-reviewed journal freely available to be accessed, downloaded, and used for research. All articles published in the IJTID are licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which is under the following terms:
Attribution ” You must give appropriate credit, link to the license, and indicate if changes were made. You may do so reasonably, but not in any way that suggests the licensor endorses you or your use.
NonCommercial ” You may not use the material for commercial purposes.
ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
